Viscogliosi Bros. Acquiring OP-1 Portfolio

Ember Therapeutics entered into a letter of intent to divest its OP-1 bone morphogenetic protein (BMP-7) product family to Viscogliosi Brothers, LLC. The transaction is slated to close in late 3Q18 or 4Q18.

The OP-1 portfolio includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in bone applications.

BMPs are members of the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us